2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: Functionally selective benzodiazepine binding site ligands on the GABAA receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 13, 2004, Pages 3441-3444

  Mitchinson, Andrew ^a   Atack, John R ^a   Blurton, Peter ^a   Carling, Robert W ^a   Castro, José L ^a   Curley, Karen S ^a   Russell, Michael G N ^a   Marshall, George ^a   McKernan, Ruth M ^a   Moore, Kevin W ^a   Narquizian, Robert ^a   Smith, Alison ^a   Street, Leslie J ^a   Thompson, Sally Anne ^a   Wafford, Keith ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIHYDROPYRAZOLO[4,3 C]PYRIDIN 3 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; DRUG BINDING SITE; ELECTROPHYSIOLOGY; LIGAND BINDING; NONHUMAN; PATCH CLAMP; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; STRUCTURE ACTIVITY RELATION; VOLTAGE CLAMP;

ANIMALS; BENZODIAZEPINES; BINDING SITES; HUMANS; KINETICS; LIGANDS; MOLECULAR STRUCTURE; PATCH-CLAMP TECHNIQUES; PYRAZOLES; PYRIDINES; RADIOLIGAND ASSAY; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942560961     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.04.085     Document Type: Article

References (13)

1. Stephenson F.A. Biochem. J. 310:1995;1
2. Mehta A.K., Ticku M.K. Brain Res. Rev. 29:1999;196
3. Rudolph U., Crestani F., Benke D., Brünig I., Benson J.A., Fritschy J.-M., Martin J.R., Bluethmann H., Möhler H. Nature. 401:1999;796
4. Sieghart W. Trends Pharmacol. Sci. 21:2000;411
5. Broughton, H. B.; Carling, R. W.; Castro Pineiro, J. L.; Guiblin, A. R.; Madin, A.; Moore, K. W.; Russell, M. G.; Street, L. J.; Patent Application WO 98/04559
6. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macauley A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. Nat. Neurosci. 3:2000;587
7. Bennet D.A., Amrick C.L., Wilson D.E., Boast C.A., Loo P., Bernard P.S., Schmutz M., Gerhardt S.C., Braunwalder A., Klebs K., Yokoyama N., Liebman J.M. Drug Dev. Res. 11:1987;219
8. Hadingham K.L., Wingrove P., Le Bourdelles B., Palmer K.J., Ragan C.I., Whiting P.J. Mol. Pharmacol. 43:1993;970
9. Wafford K.A., Whiting P.J., Kemp J.A. Mol. Pharmacol. 43:1993;240
10. Brown N., Kerby J., Bonnert T.P., Whiting P.J., Wafford K.A. Br. J. Pharmacol. 136:2002;965
11. Albaugh P.A., Marshall L., Gregory J., White G., Hutchison A., Ross P.C., Gallagher D.W., Tallman J.F., Crago M., Cassella J.V. J. Med. Chem. 45:2002;5043
12. Yokoyama, N. Patent application EP 168350
13. Atack J.R., Smith A.J., Emms F., McKernan R.M. Neuropsychopharmacology. 20:1999;255